Leaders of COVID-19 Failed To See the ‘Whole Picture’
Brent James, M.D., M.Stat., the quality and patient safety expert, finds fault with singular focus on COVID-19. Watch James' interview in this part two of three video series.
Human beings are “wonderful pattern matchers,” Brent James, M.D., M.Stat., the quality and patient safety expert, said in a video interview with Managed Healthcare Executive® this week.
“But when we ask people to assess patterns, probabilities, we are absolute crap. I don’t care how smart you are, how well trained you are.”
“I have as much as experience as anybody at this, and I am still crap,” James added.
But James said “good leaders have to look at the whole picture and balance the risks back and forth.” And James says he believes that has been in short supply in the response to the COVID-19 pandemic.
“We have had some people in the space, when challenged on this, have basically said, ‘Hey, my only assignment is Covid. I am going to focus exclusively on Covid.’”
“And I tell you, and I do mean this as a criticism,” James continued, “when I see somebody say that I realize they are saying, ‘Don’t look at me as a leader. I am not going to position myself as a leader.’ I think you have to see the whole picture.”
Asked whether he was referring to Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, James sidestepped.
“You be the judge. It is a number of people in leadership roles who needed to see the whole picture.”
James said early data show that heart disease mortality rates are increasing. International health efforts dealing with nutrition and malaria may have suffered with so much focus on COVID-19. James spoke of a secondary price to the pandemic.
“Don’t get me a wrong. I am not saying that Covid is not important. It is. I am just saying, sorry, you gotta keep an eye on the whole picture. “
Did we fail to do that?
“We are human beings and human beings, by definition, are imperfect,” answered James. “But we didn’t do as well as we could in my opinion — not just in the U.S. but worldwide.”
It is “fascinating topic” to look at why people tend to focus on a single risk, James said. “It seems to be hardwired in our evolutionary brain.”
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves First-Ever Cell Therapy Treatment for Rare Progressive Eye Disease
March 20th 2025Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells genetically engineered to produce specific therapeutic proteins. It will be available in June 2025.
Read More
